You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Relapsed/Refractory Mantle Cell Lymphoma and BTK Inhibitors: Expert Exchange and Discussion

  • Authors: Michael Wang, MD; Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
  • CME / ABIM MOC Released: 11/29/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 11/29/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for healthcare professionals, specifically hematology/oncology specialists and pathologists.

The goal of this activity is for learners to be better able to understand practical considerations with Bruton tyrosine kinase (BTK) inhibitors for the management of relapsed/refractory (R/R) mantle cell lymphoma (MCL).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Key differentiating factors between covalent and non-covalent BTK inhibitors for MCL
    • Latest clinical trial data with non-covalent BTK inhibitors for patients with MCL
  • Have greater competence related to
    • Selecting appropriate treatment for patients with MCL who are intolerant to their current BTK inhibitor
  • Demonstrate greater confidence in their ability to
    • Manage patients with MCL progressing on their current BTK inhibitor


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Michael Wang, MD

    Puddin Clark Endowed Professor
    Department of Lymphoma and Myeloma
    MD Anderson Cancer Center
    Houston, Texas, United States

    Disclosures

    Michael Wang, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; AstraZeneca; BeiGene; BioInvent; CStone Pharmaceuticals; Deciphera; DTRM Biopharma Limited; Epizyme; Genentech; InnoCare; Janssen; Juno Pharmaceuticals; Kite Pharma; Lilly; Loxo Oncology; Miltenyi Biotech; Oncternal Therapeutics; PeproMene Bio; Pharmacyclics; VelosBio
    Research funding from: Acerta; AstraZeneca; BeiGene; BioInvent; Celgene; Genentech; Genmab; InnoCare; Janssen; Juno Pharmaceuticals; Kite Pharma; Lilly; Loxo Oncology; Molecular Templates; Oncternal Therapeutics; Pharmacyclics; VelosBio; Vincerx Pharma
    Other: Honoraria from: Acerta; AstraZeneca; BeiGene; BioInvent; Dava; Epizyme; Imedex; Janssen; Kite; Miltenyi; Pharmacyclics

  • Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD

    Consultant Haematologist
    Oxford Cancer and Haematology Centre
    Churchill Hospital
    Oxford University Hospitals NHS Foundation Trust
    Oxford, United Kingdom

    Disclosures

    Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; AstraZeneca; BeiGene; Gilead; Incyte; Janssen; Kite; Loxo; Roche; Secura Bio
    Speaker or member of speakers bureau for: AbbVie; AstraZeneca; Gilead; Incyte; Janssen; Kite; Loxo; Roche; Takeda
    Research funding from: AstraZeneca; BeiGene
    Contracted researcher for: Loxo

Editor

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Sanneke Koekkoek, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Relapsed/Refractory Mantle Cell Lymphoma and BTK Inhibitors: Expert Exchange and Discussion

Authors: Michael Wang, MD; Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 11/29/2022

Valid for credit through: 11/29/2023, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to understand practical considerations with Bruton tyrosine kinase (BTK) inhibitors for the management of relapsed/refractory (R/R) mantle cell lymphoma (MCL).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print